Discover 1,734 paid clinical trials in Detroit, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,734
FeaturedActive & Responsive
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
for
Bipolar Depression
Location: 35 recruiting locations
Sponsor: Intra-Cellular Therapies, Inc.
Sex: All
Age: 10 - 17
Code: NCT06372964
Phase3, Recruiting
Active & Responsive
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
for
Relapsing Multiple Sclerosis (RMS)
Location: 61 recruiting locations
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06869785
Phase3, Recruiting
Active & Responsive
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
for
Colonic Neoplasms, Neoplasms, Colon
Location: 32 recruiting locations
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT05855200
Phase3, Recruiting
Active & Responsive
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
for
Solid Tumors
Location: 5 recruiting locations
Sponsor: Shionogi
Sex: All
Age: 18+
Code: NCT05101070
Phase1, Phase2, Recruiting
Active & Responsive
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: 21 recruiting locations
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT05787587
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: 5 recruiting locations
Sponsor: A2A Pharmaceuticals Inc.
Sex: All
Age: 18+
Code: NCT06136884
Phase1, Recruiting
Active & Responsive
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
for
Essential Thrombocythemia
Location: 14 recruiting locations
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06079879
Phase3, Recruiting
Active & Responsive
Project 2: ACHIEVE- HF
for
Heart Failure, Hypertension
Location: 1 recruiting location
Sponsor: Henry Ford Health System
Sex: All
Age: 18+
Code: NCT05330221
Recruiting
Active & Responsive
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer